Tribe Public’s (www.TribePublic.com) latest CEO spotlight managed to condense a multi‑year medtech inflection point into a crisp half hour—and still leave investors wanting a few more slides. On May 1, 2026, Modular Medical (NASDAQ: MODD) CEO Jeb Besser joined Tribe Public’s members to unpack a simple question with big implications: what happens when an “almost‑pumper” market finally meets an FDA‑cleared device built for the rest of us, not just the superusers?
A 30‑Minute Tour Through the New FDA Era
Tribe Public hosted its CEO Presentation and Q&A Webinar, “From FDA Wins to Scaling Manufacturing – What Investors Should Watch,” on Friday, May 1, 2026, at 8:00 a.m. PT / 11:00 a.m. ET. In keeping with Tribe’s reputation for efficient programming, the session ran approximately 30 minutes, pairing a focused prepared talk with a 5–10 minute live Q&A segment that allowed investors to drill into timelines, capital needs, and commercial strategy.
Besser’s formal remarks were framed under the title “From FDA Wins to Scaling Manufacturing – What Investors Should Watch,” setting the tone for a discussion that sat at the intersection of regulation, innovation, and recurring‑revenue hardware. By registering, attendees also joined Tribe Public’s membership base, ensuring they will receive future invitations to CEO briefings, sector spotlights, and investor wish‑list events.
FDA Clearance: From Risk Factor to Revenue Roadmap
The central catalyst for this webinar was Modular Medical’s April 9, 2026 announcement that the U.S. Food and Drug Administration had granted 510(k) clearance for its Pivot tubeless insulin patch pump. Clearance formally opens the door to U.S. commercial sales and, more importantly in Wall Street shorthand, converts a binary regulatory overhang into an execution story centered on manufacturing, adoption, and margin.
For investors who spend their days swimming in risk factors, the Pivot clearance is notable on several fronts. It de‑risks the core product platform, validates the company’s regulatory strategy, and starts the clock on a commercial timeline that targets initial customer shipments by the end of the second quarter of 2026, with European CE Mark ambitions in the late‑2026 to early‑2027 window. In other words, the market has shifted from asking “if” to asking “how fast” and “how profitably” this platform can scale.
Pivot: A Patch Pump Designed for “Almost‑Pumpers”
At the heart of the story is Pivot, billed as the first two‑part tubeless patch pump to pair a removable 3 mL insulin reservoir with a disposable battery and smartphone connectivity for bolus dosing and monitoring. Unlike traditional, tube‑dependent pumps that can leave patients feeling tethered, Pivot’s architecture is deliberately minimalist: no tubing, no recharging regimen, and the ability to detach for showers, sports, or moments when discretion is the better part of glycemic control.biospace+1
Where Pivot really differentiates itself is in its target audience. Modular Medical estimates that roughly 70% of insulin‑dependent adults remain on multiple daily injections—despite 4.8 million individuals in the U.S. requiring daily insulin and only about 20% using pumps—largely because existing devices are viewed as complex, cumbersome, or costly. This “almost‑pumper” cohort is precisely where Pivot is aimed, with a design philosophy that seeks to simplify onboarding, reduce hardware burden, and position the system as an affordable step‑up from syringes, not a lifestyle overhaul reserved for early adopters .
Manufacturing at Scale: From Validation Lots to Real‑World Users
For a company transitioning from development to commercialization, the conversation naturally shifts from lab bench to assembly line. Modular Medical reports that manufacturing validation lots for Pivot are already underway, with initial capacity designed to support approximately 6,000 users and a platform architecture that can scale production while keeping unit costs competitive.
Investors listening to the webinar were particularly attuned to the interplay between capacity, capital, and cadence. Recent corporate actions—ranging from financings and a 1‑for‑30 reverse split to the establishment of a sizeable shelf registration—underscore that management is building both the physical and financial infrastructure to support a commercial ramp, even as the stock has experienced volatility around dilution events. In that context, the Q&A on manufacturing scale‑up was less about whether Modular Medical can make pumps and more about how quickly it can convert factory throughput into recurring revenue.
Software, AID, and the Longer‑Term Technology Stack
While the immediate story is about getting the first wave of Pivot users on therapy, Besser’s narrative also pointed to a layered roadmap on the software side. Ongoing development efforts include features such as variable bolus options, enhanced alarms, and future compatibility with ACE and automated insulin delivery (AID) ecosystems—capabilities that would move Pivot from a novel patch pump into a connected, data‑rich platform.
For healthcare sector oriented investors, this is where the story begins to compound. As software functionality expands, each hardware sale becomes a gateway to deeper integration with clinical workflows, payer expectations, and potential algorithmic partners, reinforcing the subscription‑like dynamics that have made diabetes technology a durable growth theme in healthcare portfolios. In short, Pivot’s first act is hardware, but the franchise value increasingly resides in the code.
Tribe Public’s Role: Curating the “Next” Conversations
The Modular Medical webinar also served as a real‑time illustration of Tribe Public’s model: connecting company management teams with an audience that ranges from family offices and portfolio managers to accredited investors, analysts, and media. Headquartered in San Francisco, Tribe Public curates both virtual and in‑person events across dozens of venues, with agendas frequently shaped by member wish lists that surface the next round of CEOs, sectors, and catalysts the community wants to hear from directly.
By design, these webinar-based sessions are compact: roughly 30 minutes of prepared remarks followed by targeted Q&A, enough to move beyond the press release but not so sprawling that investors need a second cup of coffee to reach the outlook slide. And in the case of Modular Medical (NASDAQ: MODD), the format offered a timely forum to translate a fresh FDA clearance into a more nuanced investor dialogue about manufacturing, market penetration, and the practical realities of serving millions of insulin‑dependent patients who are ready for something better than needles, but not interested in wearing a spaceship on their waistband.
